Overview

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S